Trial Profile

A phase 3 study of Q-Octreotide (MTD201) for carcinoid cancer and acromegaly

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 12 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Octreotide (Primary)
Indications Acromegaly; Malignant carcinoid syndrome
Focus Pharmacokinetics; Registrational
Sponsors Biodexa Pharmaceuticals

Most Recent Events

16 May 2023 According to Biodexa Pharmaceuticals, 20-F filing, Midatech has changed its name to Biodexa Pharmaceuticals
29 Jan 2019 According to a Midatech media release, this trial is expected to begin in H2 2019.
06 Sep 2018 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com